focus -WSS

focus

author：knowledge 2025-09-14 10:05:49 - browse：27

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Surgery pushed Ben Carson to fame

focus

WSS

Updated Covid vaccine has 54% effectiveness, new study suggests

Adopting new red light myopia treatments may be short

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Dario to buy mental health app maker Twill in cash and stock deal

Texas Medical Board asked to define abortion emergency exception

entertainment

focus

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Continuity nursing helped my family in our darkest PICU moments

AI gets buy

Walensky prepares to leave CDC — and Congress — behind

Top private equity targets in 2023: cardiology, clinical trials, lasers

Trump demands the U.S. pay no more for drugs than other countries … again

Gene therapy for Afghan refugees’ infant will be fully covered

State Dept. review finds Biden bears some blame for Afghanistan failures

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

focus

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Medicare Advantage plans can’t deny care with AI, CMS warns

Antivenom research: Lessons from HIV applied in search for universal antidote

The CDC's new social media misinformation war

Readout LOUD: Venture capital, Gilead, and more M&A

Alabama IVF ruling threatens families facing fatal genetic disease

focus

focus

hotspot

hotspot